Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles

Panyam, Jayanth; Dali, Manisha M.; Sahoo, Sanjeeb K.; Ma, Wenxue; Chakravarthi, Sudhir S.; Amidon, Gordon L.; Levy, Robert J.; Labhasetwar, Vinod

doi:10.1016/s0168-3659(03)00328-6

Cited by 468 publications

(277 citation statements)

References 24 publications

Supporting

Mentioning

256

Contrasting

Unclassified

Order By: Relevance

“…The polymer degradation rate of particles is not influenced by size. In the study of BSA-encapsulated PLGA particles with sizes of 0.1, 1, and 10 µm, the polymer degradation rate did not significantly vary (36).…”

Section: Discussionmentioning

confidence: 91%

Antibody Response is Differentially Influenced by PLGA-PAD4 Particle Characteristics

Manish

Bhatnagar

2017

Int J Infect

View full text Add to dashboard Cite

Background: Anthrax, as a zoonotic disease, is considered a major bioterror threat. Development of effective prophylactic approaches is needed to combat this disease. The protective antigen domain 4 (PAD4) has been extensively studied as a vaccine candidate against anthrax. Previously, we showed that PAD4 can be successfully encapsulated in poly (lactide-co-glycolide) (PLGA)-based particulate systems. Objectives: We aimed to determine if there is an intricate relationship between the parameters of PLGA particulate process and the associated immunogenicity. Methods: In this study, PLGA (50:50) and PLGA (85:15) with a similar molecular weight were used as the polymer variants. Polymer variants were evaluated using 3 adaptations of w/o/w solvent evaporation method. Six variants of PLGA-PAD4 particulate systems were developed and studied for size, antigen content, and immunogenicity. Results: NaCl in the external aqueous phase was required to achieve nonporous and spherical microparticles. Particle size was found to be dependent on the applied methods, and there was no significant difference in size by varying the PLGA compositions. PLGA variants showed a differential behavior with antigen encapsulation in the evaluated methods. The hydrophobic particulate

show abstract

Section: Discussionmentioning

confidence: 91%

Antibody Response is Differentially Influenced by PLGA-PAD4 Particle Characteristics

Manish

Bhatnagar

2017

Int J Infect

View full text Add to dashboard Cite

show abstract

“…molecular weight, copolymer ratio and crystallinity) (Park, 1995) and the drug (Miyajima et al, 1998), as well as key quality attributes (e.g. particle size, morphology, porosity, and drug loading) of the PLGA microspheres may affect in vitro drug release characteristics (Dunne et al, 2000;Ehtezazi and Washington, 2000;Luan et al, 2006;Panyam et al, 2003). Risperidone, a tertiary amine drug with a pKa of 8.18 (20°C), has been shown to catalyze PLGA hydrolysis and degradation, thus resulting in a dramatic decrease in polymer molecular weight (Fig.…”

Section: Discussionmentioning

confidence: 99%

A reproducible accelerated in vitro release testing method for PLGA microspheres

Shen

Lee

Choi

et al. 2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

The objective of the present study was to develop a discriminatory and reproducible accelerated in vitro release method for long-acting PLGA microspheres with inner structure/porosity differences. Risperidone was chosen as a model drug. Qualitatively and quantitatively equivalent PLGA microspheres with different inner structure/porosity were obtained using different manufacturing processes. Physicochemical properties as well as degradation profiles of the prepared microspheres were investigated. Furthermore, in vitro release testing of the prepared risperidone microspheres was performed using the most common in vitro release methods (i.e. sample-andseparate and flow through) for this type of product. The obtained compositionally equivalent risperidone microspheres had similar drug loading but different inner structure/porosity. When microsphere particle size appeared similar, porous risperidone microspheres showed faster microsphere degradation and drug release compared with less porous microspheres. Both in vitro release methods investigated were able to differentiate risperidone microsphere formulations with differences in porosity under real-time (37°C) and accelerated (45°C) testing conditions. Notably, only the accelerated USP apparatus 4 method showed good reproducibility for highly porous risperidone microspheres. These results indicated that the accelerated USP apparatus 4 method is an appropriate fast quality control tool for long-acting PLGA microspheres (even with porous structures). Graphical Abstract*

show abstract

“…Particle sizes of nanocarrier also influence some of the very important characteristics such as degradation and clearance. It was reported that degradation of particles is size-dependent and degradation products formed within the particle can diffuse freely to the surface if they are from smaller particles (Dunne et al, 2000;Panyam et al, 2003). Particle size more importantly dictates the endocytic mechanism which will be engaged to internalize the nanocarrier.…”

Section: Effect Of Size and Shape Of Nanoparticles In Subcellular Tramentioning

confidence: 99%

Nanocarriers for Cytosolic Drug and Gene Delivery in Cancer Therapy

Palakurthi¹,

Yellepeddi²,

Kumar³

2011

Biomedical Engineering, Trends, Research and Technologies

View full text Add to dashboard Cite

Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles

Cited by 468 publications

References 24 publications

Antibody Response is Differentially Influenced by PLGA-PAD4 Particle Characteristics

Antibody Response is Differentially Influenced by PLGA-PAD4 Particle Characteristics

A reproducible accelerated in vitro release testing method for PLGA microspheres

Nanocarriers for Cytosolic Drug and Gene Delivery in Cancer Therapy

Contact Info

Product

Resources

About